Ageless Biotech Announces FDA Accepted Phase IIb Study Targeting Moderate to Severe Osteoarthritis of the Knee Joint

Ageless Biotech, Inc. acquired a US FDA Investigational New Drug Application for the treatment of osteoarthritis of the knee, using minimally manipulated adipose derived stem cells without enzymes or other chemicals through a proprietary process of a well-known method referred to as stromal vascular fraction.